How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Neoantigen Vaccine Market
- By Vaccine Type: Personalized Neoantigen Vaccines, Shared Neoantigen Vaccines, Peptide-based Neoantigen Vaccines, mRNA-based Neoantigen Vaccines, Dendritic Cell-based Neoantigen Vaccines
- By Cancer Indication: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Colorectal Cancer, Glioblastoma, Ovarian Cancer, Pancreatic Cancer
- By Technology Platform: Next-Generation Sequencing (NGS), Bioinformatics and AI-driven Epitope Prediction, Synthetic Peptide Synthesis, mRNA Technology, Dendritic Cell Engineering
- By End User: Hospitals and Cancer Treatment Centers, Research Institutes, Contract Research Organizations (CROs), Biopharmaceutical Companies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Personalized Neoantigen Vaccines leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.169 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Neoantigen Vaccine Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 5
Cancer Indication 6
Technology Platform 5
End User 4
Companies profiled
BioNTech SE
Moderna Inc.
Gritstone Oncology Inc.
Neon Therapeutics (acquired by BioNTech)
Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programs
Genocea Biosciences Inc.
Immatics Biotechnologies GmbH
Kite Pharma (a Gilead company)
Adaptimmune Therapeutics plc
Vaccibody AS
CureVac AG
Agenus Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BioNTech SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Gritstone Oncology Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Neon Therapeutics (acquired by BioNTech)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programs
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Genocea Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Immatics Biotechnologies GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Kite Pharma (a Gilead company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Adaptimmune Therapeutics plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vaccibody AS
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →CureVac AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Agenus Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Mologen AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →NantKwest Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →OncoImmunity AS
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,970M by 2033 · 3.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Personalized Neoantigen Vaccines53.7
- Shared Neoantigen Vaccines7.0
- Peptide-based Neoantigen Vaccines19.0
- mRNA-based Neoantigen Vaccines6.6
- Dendritic Cell-based Neoantigen Vaccines13.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$968.6M → $1,320M · 3.9%
Europe$675.1M → $928.2M · 4.1%
Asia Pacific$616.4M → $933.0M · 5.3%
Latin America$381.6M → $462.2M · 2.4%
Middle East and Africa$293.5M → $355.8M · 2.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.802026
3.822027
3.832028
3.832029
3.852030
3.852031
3.862032
3.892033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BioNTech SE15.3
- Moderna Inc.13.3
- Gritstone Oncology Inc.7.1
- Neon Therapeutics (acquired by BioNTech)18.0
- Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programs7.8
- Genocea Biosciences Inc.10.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type20.6%
Cancer Indication21.3%
Technology Platform40.8%
End User17.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe23.2
- Asia Pacific23.3
- Latin America11.6
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BioNTech SE | 91 | 81 | 74 | 90 | 88 | 77 | 84 |
| Moderna Inc. | 78 | 82 | 78 | 80 | 84 | 84 | 81 |
| Gritstone Oncology Inc. | 75 | 70 | 86 | 83 | 84 | 83 | 80 |
| Neon Therapeutics (acquired by BioNTech) | 67 | 74 | 58 | 61 | 71 | 63 | 66 |
| Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programs | 67 | 64 | 72 | 54 | 58 | 63 | 63 |
| Genocea Biosciences Inc. | 57 | 68 | 68 | 58 | 51 | 67 | 62 |
| Immatics Biotechnologies GmbH | 55 | 63 | 61 | 51 | 47 | 55 | 55 |
| Kite Pharma (a Gilead company) | 51 | 51 | 41 | 39 | 50 | 48 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BioNTech SE
- Moderna Inc.
- Gritstone Oncology Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BioNTech SE | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Moderna Inc. | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Gritstone Oncology Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Neon Therapeutics (acquired by BioNTech) | − | ◐ | ◐ | ◐ | ✓ | − |
| Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programs | ✓ | ◐ | ◐ | ◐ | − | − |
| Genocea Biosciences Inc. | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Immatics Biotechnologies GmbH | − | − | ◐ | − | − | − |
| Kite Pharma (a Gilead company) | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BioNTech SE84
2Moderna Inc.81
3Gritstone Oncology Inc.80
4Neon Therapeutics (acquired by BioNTech)66
5Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programs63
6Genocea Biosciences Inc.62
7Immatics Biotechnologies GmbH55
8Kite Pharma (a Gilead company)47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
BioNTech SEModerna Inc.Gritstone Oncology Inc.
Contender3
Focused players with pockets of strength.
Neon Therapeutics (acquired by BioNTech)Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programsGenocea Biosciences Inc.
Niche2
Specialists in a single segment or region.
Immatics Biotechnologies GmbHKite Pharma (a Gilead company)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Neoantigen Vaccine Market — a $233M beachhead inside a $4.58B market.
Beachhead (SOM)$233Mobtainable near-term
Serviceable (SAM)$1.65Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Personalized Neoantigen Vaccines
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer79 fit
Shared Neoantigen Vaccines
Strong fit — clear ROI and a fast path to value.
End user69 fit
Peptide-based Neoantigen Vaccines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cancer Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology Platform
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Neoantigen Vaccine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation15%
Closed-won6%
$15.9KCAC
$81KLTV
5.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Neoantigen Vaccine Market is a resilient opportunity — $5.59B by 2033, compounding at 4.7%.
TAM · 2025$3.86Btoday
TAM · 2033$5.59Bforecast
CAGR4.7%2027–2033
Cumulative$42.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.59BTotal addressable market
SAM$2.08BServiceable available market
SOM$441MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.59BLarge & growingTAM by 2033 at 4.7% CAGR
$2.08BServiceable nowreachable with today’s model
$441MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.36BBear3.1% CAGR
$5.59BBase4.7% CAGR
$7.16BBull6.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cancer Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Neoantigen Vaccine Market — a $5.09B market by 2033. Plan: grow share from 8.1% to 12.7%.
Market size · 2033$5.09Btotal addressable
Market CAGR11.1%2027–2033
Target share12.7%from 8.1% today
Revenue ambition$646Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.1% | 12.7% | On track |
| Revenue | $421M | $646M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 36.9% | 39.4% | Ahead |
| Customer retention | 88.4% | 92.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cancer Indication capability
A defensible second engine — invest in Cancer Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cancer Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $85M capacity & capability investment
- Greenlight bolt-on M&A in Cancer Indication
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Neoantigen Vaccine Market conversation — a $5.92B market you can size, segment and defend in minutes.
Market size · 2033$5.92Btotal opportunity
Growth9.8%CAGR to 2033
Addressable buyers1,085+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 3 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
BioNTech SEModerna Inc.Gritstone Oncology Inc.Neon Therapeutics (acquired by BioNTech)Immuno-oncology companies like Genentech (Roche) with neoantigen vaccine programsGenocea Biosciences Inc.Immatics Biotechnologies GmbHKite Pharma (a Gilead company)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Neoantigen Vaccine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Neoantigen Vaccine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Neoantigen Targeted Therapy Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportNeoantigen Peptides Manufacturing Market
Market size, share, segmentation and regional forecast.
$393M market · 2025 base year
View reportNeoantigen Cancer Vaccine Market
Market size, share, segmentation and regional forecast.
$835M market · 2025 base year
View reportNematode Growth Media (NGM) Powder Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportNematode Growth Media (NGM) Plates Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportNelfinavir Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportNelaton Catheter Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportNeisseria Gonorrhoeae RT-PCR Detection Kit Market
Market size, share, segmentation and regional forecast.
$820M market · 2025 base year
View reportNeisseria Gonorrhoeae Medium Market
Market size, share, segmentation and regional forecast.
$457M market · 2025 base year
View reportNeisseria Gonorrhoeae Detection Kit Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportNegatoscope Market
Market size, share, segmentation and regional forecast.
$767M market · 2025 base year
View reportNegative Pressure Wound Treatment Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.